BPC-157 TB-500 FAQ

What is the Wolverine peptide blend?

A research-community name for a two-peptide pairing of BPC-157 (a cytoprotective, angiogenic pentadecapeptide) and TB-500 (the Ac-LKKTETQ actin-binding fragment of Thymosin Beta-4) ^[1][3]. It is not a single chemical entity or an approved product.

What is BPC-157 and TB-500?

BPC-157 is a synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) derived from a human gastric-juice protein; TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) from the actin-binding region of Thymosin Beta-4 ^[1][3]. The blend pairs the two.

What is the BPC-157 and TB-500 blend used for in research?

It is studied in animal models of tissue repair — tendon, ligament, muscle, and wound healing — with BPC-157 supplying a cytoprotective and angiogenic signal ^[1][2] and TB-500 / Thymosin Beta-4 supplying a cytoskeletal cell-migration signal ^[3][4].

How does TB-500 work (actin / Thymosin Beta-4)?

TB-500's LKKTETQ motif binds monomeric G-actin 1:1 and sequesters it by capping both ends, regulating the actin dynamics that drive cell migration, re-epithelialization, and progenitor mobilization ^[3]. The structural basis was established by crystallography of a Thymosin Beta-4-actin complex ^[3].

How does BPC-157 work compared to TB-500?

BPC-157 acts mainly extracellularly as a cytoprotective and pro-angiogenic signal, up-regulating VEGFR2 with downstream Akt-eNOS effects ^[2], while TB-500 acts on the intracellular cytoskeleton via G-actin sequestration ^[3]. The pathways are described as complementary and largely non-overlapping.

Do BPC-157 and TB-500 act through the same pathway?

No. BPC-157 works through extracellular VEGFR2-Akt-eNOS signaling ^[2]; TB-500 / Thymosin Beta-4 works through intracellular G-actin sequestration that governs cell migration ^[3]. This separation is the basis of the "synergy" claim, which remains theoretical ^[5].

What does TB-500 stand for and how does it relate to Thymosin Beta-4?

TB-500 is a synthetic N-acetylated heptapeptide (Ac-LKKTETQ) corresponding to residues 17-23 — the actin-binding region — of Thymosin Beta-4, the ubiquitous 43-amino-acid intracellular G-actin-sequestering protein ^[3]. Most efficacy data attributed to "TB-500" were actually generated with the full-length protein, not the 7-mer ^[4].

Why are BPC-157 and TB-500 combined (the Wolverine stack)?

The rationale is complementary mechanisms: BPC-157's VEGFR2-Akt-eNOS angiogenesis and cytoprotection ^[2] alongside TB-500 / Thymosin Beta-4's G-actin sequestration and cell migration ^[3]. This complementarity is theoretical — no controlled combination study has demonstrated it ^[5].

Is there any study showing BPC-157 and TB-500 work better together (synergy)?

No published controlled study defines a synergy ratio, dose, or endpoint for the two given together. The 2025 systematic review of BPC-157 makes no mention of TB-500 or combination use ^[5]; the "better together" claim extrapolates from each peptide's independently characterized mechanism.

Are there human clinical trials on the BPC-157 + TB-500 combination?

No. There are no controlled clinical trials of the combination. Human data exist only for the individual constituents and are thin: three small BPC-157 pilot studies, and Phase 1 safety/PK data for full-length thymosin beta-4 — not the TB-500 fragment ^[5][8].

Does the BPC-157 TB-500 blend help tendon and ligament injuries?

In animal models, BPC-157 accelerated healing of a transected rat Achilles tendon across biomechanical and microscopic measures ^[1], and Thymosin Beta-4 promoted cell migration and repair-cell recruitment relevant to connective tissue ^[4][6]. These are preclinical findings, not human evidence for the blend.

Does BPC-157 and TB-500 help muscle tears and recovery?

Preclinical and review evidence describes musculoskeletal-repair activity for BPC-157 ^[1], and a myoblast-chemoattractant role for Thymosin Beta-4 ^[6]. A 2025 systematic review rates the BPC-157 musculoskeletal evidence as level IV-V — the lowest tiers ^[5]; no human combination data exist.

What is the half-life of BPC-157 and TB-500?

No validated human pharmacokinetic half-life exists for either constituent at research-use doses, nor for the blend. BPC-157's elimination half-life was reported as under 30 minutes in a rat/dog PK study ^[10]; human intravenous thymosin beta-4 showed dose-proportional PK with no specific half-life established for the TB-500 heptapeptide ^[4].

How do you reconstitute a BPC-157 / TB-500 blend (10mg)?

Both constituents are supplied as lyophilized powders, reconstituted in bacteriostatic or sterile water and refrigerated; a common practice is to reconstitute the two separately or in a shared vial ^[10]. Product identity, purity, and the actual BPC-157:TB-500 ratio in unregulated material are not guaranteed. This describes laboratory handling, not human-use guidance.

How often should you inject BPC-157 and TB-500?

There is no validated dose or schedule for the blend. Community "loading then maintenance" protocols and fixed-ratio vials (e.g. 10 mg + 10 mg) have no controlled-trial basis ^[5]. The underlying animal studies used per-body-weight doses by routes — often intraperitoneal — that do not translate to human guidance ^[1][4].

What are the side effects of BPC-157 and TB-500?

Human safety data for the blend do not exist. Recent reviews describe both peptides as investigational with limited human safety data ^[8][9]; a theoretical tumor and angiogenesis concern attaches to thymosin beta-4 ^[4]. Findings are reported in research animals, not as human safety guidance.

Does TB-500 cause cancer or promote tumor growth?

Thymosin beta-4 is implicated in tumor metastasis and angiogenesis, so the same pro-migratory, pro-angiogenic properties that aid repair could theoretically support tumor progression — a recognized safety consideration, more so when two pro-repair peptides are combined ^[4]. This is a theoretical concern from preclinical literature, not a human finding for the blend.

What is the difference between BPC-157 and TB-500?

BPC-157 is a 15-amino-acid gastric-juice-derived peptide acting as an extracellular cytoprotective and pro-angiogenic signal ^[1][2]; TB-500 is the 7-amino-acid Ac-LKKTETQ actin-binding fragment of Thymosin Beta-4 acting on the intracellular cytoskeleton ^[3]. Their mechanisms are complementary and largely non-overlapping.

How do you cycle BPC-157 and TB-500?

Community "loading then maintenance" cycles for the blend have no basis in controlled human trials. No validated cycle, dose, or BPC-157:TB-500 ratio exists; the underlying evidence is preclinical and single-compound ^[5]. A rat study even found higher thymosin beta-4 doses gave no benefit ^[4].

Do BPC-157 and TB-500 promote angiogenesis (new blood vessels)?

Both are reported to promote angiogenesis by distinct routes in research models: BPC-157 up-regulates and internalizes VEGFR2 with downstream Akt-eNOS signaling ^[2], while Thymosin Beta-4 promotes endothelial migration and angiogenesis ^[4]. These are preclinical mechanism findings.

Does the BPC-157 TB-500 blend help wound healing?

Thymosin Beta-4 promotes re-epithelialization, cell migration, reduced myofibroblast and scar formation, and angiogenesis in animal wound work ^[4], and BPC-157 supports multi-tissue repair ^[1]. These are preclinical, single-compound findings, not human evidence for the blend.

Is Wolverine (BPC-157 + TB-500) legal?

Neither peptide is an FDA-approved drug, and the blend has no approved indication. Both are currently in FDA's 503A "Category 2" (effective Sept 29, 2023), so compounding-pharmacy access is presently restricted ^[13][14]. Both are on the July 23-24, 2026 PCAC agenda, so the status is under active review ^[11].

Can you get BPC-157 from a compounding pharmacy?

Currently, access is restricted: FDA placed BPC-157 in 503A "Category 2" effective September 29, 2023, outside its enforcement-discretion policy for 503A compounding ^[13]. BPC-157 is on the July 23-24, 2026 PCAC agenda as a 503A bulks-list candidate, so this is under active review — but no change has been decided ^[11].

What is the FDA 503A status of Wolverine (BPC-157 + TB-500)?

Both components are 503A "Category 2" bulk drug substances, effective September 29, 2023, which falls outside FDA's enforcement-discretion policy ^[13][14]. Both BPC-157 and TB-500 are on the scheduled July 23-24, 2026 PCAC agenda as candidates being considered for the 503A Bulks List ^[11][12].